Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Blueprint Medicines Corp shares valued at $221,098 were purchased by KATHRYN D HAVILAND on Apr 01 ’25. At $88.51 per share, KATHRYN D HAVILAND acquired 2,498 shares.
Also, Rossi Christina sold 2,274 shares, netting a total of over 216,075 in proceeds. Following the sale of shares at $95.02 each, the insider now holds 69,266 shares.
Before that, Christina Rossi had added 9,096 shares to its account. In a trade valued at $811,363, the Officer bought Blueprint Medicines Corp shares for $89.20 each.
Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid March. As of March 17, 2025, Jefferies has initiated its “Buy” rating for BPMC. Earlier on March 07, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for BPMC stock.
Analyzing BPMC Stock Performance
During the last five days, there has been a drop of approximately -0.78%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 3.20%. Shares of the company reached a 52-week high of $118.25 on 01/27/25 and a 52-week low of $84.55 on 04/01/25. A 50-day SMA is recorded $97.09, while a 200-day SMA reached $96.54.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 86.61, which, if violated, would cause prices to drop to 83.21. In the upper region, resistance lies at 91.90. The next price resistance is at 93.79. RSI (Relative Strength Index) is 47.63 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.92, which suggests the price will decrease in the coming days. Percent R is at 52.40%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
